Cancellation of the offering was a Great Move, given
Cancellation of the offering was a Great Move, given "market conditions."
Hoss, I would wait a week or so for the full explanation in the Annual Report due April 1 this year. Then interested parties will get the full explanation of "market conditions" and you can go back to making statements about Mr. Berman and DECN that will survive on message boards because the statements will end with a question mark.
With the Annual Report due next week I do not believe the company will put out news release so beloved by stock traders.
2
Decision Diagnostics Corp (DECN) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Adobe's Options Activity Highlights In the world of finance, significant trades often signal important market sentiments. Recently, major investors have moved toward a bearish outlook on Adobe. Analyzing the options history for Adobe (NASDAQ: ADBE), we've identified a total of 67 significant trades. Our insights reveal that approximately 41% of these trades have been...
Continue Reading
Indonesia's Maritime Security Efforts Intensify Recently, Indonesia's maritime security has been under increased scrutiny as incidents involving a Chinese coast guard vessel continue to escalate. This week, a Chinese vessel was driven from Indonesian waters not once, but twice, after interfering with a critical energy survey conducted by Pertamina, the state energy...
Continue Reading
Welcome to the Future of Game Development Upheaval Games, founded by veterans from the gaming industry, embraces a new frontier in game design with the introduction of The Dreamer Portal. This innovative web-based interface allows creators to effortlessly build immersive game content with just a simple prompt. Imagine the power of crafting unique creatures, items, and...
Continue Reading
Alvotech and Advanz Pharma Collaborate for Biosimilar Approval REYKJAVIK and LONDON – Alvotech (NASDAQ: ALVO), a renowned biotechnology firm, along with Advanz Pharma, a leading global pharmaceutical company, has shared important news regarding the marketing approval of Gobivaz®, a proposed biosimilar to Simponi® (golimumab). This biologic treatment is designed for...
Continue Reading
Remote Patient Monitoring Set for Dynamic Growth The increasing prevalence of chronic conditions worldwide is expected to significantly accelerate the growth of the remote patient monitoring (RPM) market. As conditions like hypertension, diabetes, and cardiovascular diseases become more common, coupled with an aging population, healthcare systems face immense pressure to...
Continue Reading
